{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:29:32Z","timestamp":1793305772050,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2020,6,1]]},"DOI":"10.1001\/jamaneurol.2020.0387","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T11:32:30Z","timestamp":1586172750000},"page":"735","source":"Crossref","is-referenced-by-count":336,"title":["Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals"],"prefix":"10.1001","volume":"77","author":[{"given":"Reisa A.","family":"Sperling","sequence":"first","affiliation":[{"name":"Center for Alzheimer Research and Treatment, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard Aging Brain Study, Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Donohue","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rema","family":"Raman","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Kai","family":"Sun","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Yaari","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Holdridge","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Siemers","sequence":"additional","affiliation":[{"name":"Eli Lilly & Co, Indianapolis, Indiana"},{"name":"Siemers Integration LLC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for Alzheimer Research and Treatment, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Harvard Aging Brain Study, Departments of Neurology and Radiology, Massachusetts General Hospital, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[{"name":"Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the A4 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"noi200010r1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/(ISSN)1531-8249","article-title":"Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease.","volume":"45","author":"Price","year":"1999","journal-title":"Ann Neurol"},{"issue":"3","key":"noi200010r2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi200010r3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease.","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"pt 1","key":"noi200010r4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/brain\/awt286","article-title":"Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer\u2019s disease.","volume":"137","author":"Lim","year":"2014","journal-title":"Brain"},{"issue":"1","key":"noi200010r5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1001\/jamaneurol.2015.3098","article-title":"Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community.","volume":"73","author":"Petersen","year":"2016","journal-title":"JAMA Neurol"},{"issue":"9","key":"noi200010r6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jalz.2017.01.018","article-title":"Early and late change on the preclinical Alzheimer\u2019s cognitive composite in clinically normal older individuals with elevated amyloid \u00df.","volume":"13","author":"Mormino","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"22","key":"noi200010r7","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"noi200010r8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1001\/jama.2019.7437","article-title":"Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia.","volume":"321","author":"Jack","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"noi200010r9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease.","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement"},{"key":"noi200010r10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.trci.2018.08.005","article-title":"Amyloid-associated increases in longitudinal report of subjective cognitive complaints.","volume":"4","author":"Amariglio","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10","key":"noi200010r11","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S1474-4422(13)70194-7","article-title":"Preclinical Alzheimer\u2019s disease and its outcome: a longitudinal cohort study.","volume":"12","author":"Vos","year":"2013","journal-title":"Lancet Neurol"},{"key":"noi200010r12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neurobiolaging.2017.12.018","article-title":"Amyloid pathology in the progression to mild cognitive impairment.","volume":"64","author":"Insel","year":"2018","journal-title":"Neurobiol Aging"},{"issue":"4","key":"noi200010r13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"noi200010r14","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1212\/WNL.0b013e31828ab35d","article-title":"Meta-analysis of amyloid-cognition relations in cognitively normal older adults.","volume":"80","author":"Hedden","year":"2013","journal-title":"Neurology"},{"issue":"228","key":"noi200010r15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"issue":"1","key":"noi200010r16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-015-0112-7","article-title":"Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.","volume":"7","author":"Harkins","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi200010r17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamaneurol.2014.3375","article-title":"Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer\u2019s Disease Cooperative Study Cognitive Function Instrument.","volume":"72","author":"Amariglio","year":"2015","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi200010r18","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00259-016-3601-4","article-title":"Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging.","volume":"44","author":"Pontecorvo","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"noi200010r19","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.jalz.2012.10.007","article-title":"Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer\u2019s disease dementia, mild cognitive impairment, and normal aging.","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"1","key":"noi200010r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000334607","article-title":"Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4\/4) among patients diagnosed with Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"38","author":"Ward","year":"2012","journal-title":"Neuroepidemiology"},{"issue":"3","key":"noi200010r21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neulet.2010.02.016","article-title":"Amyloid load in nondemented brains correlates with APOE e4.","volume":"473","author":"Caselli","year":"2010","journal-title":"Neurosci Lett"},{"issue":"6","key":"noi200010r22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1001\/jamaneurol.2017.0244","article-title":"Evaluation of amyloid protective factors and Alzheimer disease neurodegeneration protective factors in elderly individuals.","volume":"74","author":"Vemuri","year":"2017","journal-title":"JAMA Neurol"},{"issue":"14","key":"noi200010r23","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.2017.3090","article-title":"Association between midlife vascular risk factors and estimated brain amyloid deposition.","volume":"317","author":"Gottesman","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"noi200010r24","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jalz.2018.04.010","article-title":"Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer\u2019s disease: findings from three well-characterized cohorts.","volume":"14","author":"Buckley","year":"2018","journal-title":"Alzheimers Dement"},{"key":"noi200010r25","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.1879","article-title":"Associations of physical activity and \u00df-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults.","author":"Rabin","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"noi200010r26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1212\/WNL.0000000000002914","article-title":"The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE.","volume":"87","author":"Gottesman","year":"2016","journal-title":"Neurology"},{"issue":"7","key":"noi200010r27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2174\/1567205012666150530203214","article-title":"Structural MRI predictors of late-life cognition differ across African Americans, Hispanics, and whites.","volume":"12","author":"Zahodne","year":"2015","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"noi200010r28","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1212\/WNL.0000000000001834","article-title":"Mixed pathology is more likely in black than white decedents with Alzheimer dementia.","volume":"85","author":"Barnes","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"noi200010r29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.25395","article-title":"The impact of amyloid-beta and tau on prospective cognitive decline in older individuals.","volume":"85","author":"Sperling","year":"2019","journal-title":"Ann Neurol"},{"issue":"9","key":"noi200010r30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaneurol.2018.1123","article-title":"Interactive associations of vascular risk and \u00df-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study.","volume":"75","author":"Rabin","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"noi200010r31","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ana.v86.6","article-title":"Amyloid, vascular, and resilience pathways associated with cognitive aging.","volume":"86","author":"Vemuri","year":"2019","journal-title":"Ann Neurol"},{"issue":"14","key":"noi200010r32","doi-asserted-by":"publisher","first-page":"e1567","DOI":"10.1212\/WNL.0000000000007248","article-title":"ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes.","volume":"92","author":"Soldan","year":"2019","journal-title":"Neurology"},{"issue":"19","key":"noi200010r33","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"noi200010r34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(17)30077-7","article-title":"Age-specific and sex-specific prevalence of cerebral \u00df-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study.","volume":"16","author":"Jack","year":"2017","journal-title":"Lancet Neurol"},{"issue":"4","key":"noi200010r35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1474-4422(18)30029-2","article-title":"Cognitive and neuroimaging features and brain \u00df-amyloidosis in individuals at risk of Alzheimer\u2019s disease (INSIGHT-preAD): a longitudinal observational study.","volume":"17","author":"Dubois","year":"2018","journal-title":"Lancet Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2763540\/jamaneurology_sperling_2020_oi_200010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T11:44:57Z","timestamp":1695987897000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2763540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.0387","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}